Glimepiride Placebo

DRUG4 trials

Conditions

Diabetes Mellitus, Type 2Diabetes Mellitus, Type IIType 2 Diabetes Mellitus

Phase 3

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2010-11-11End: 2018-08-21Updated: 2020-01-07

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

CompletedNCT01682759

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2012-09-10End: 2015-01-26Updated: 2018-09-07

A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

TerminatedNCT01863667

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-07-08End: 2014-04-03Updated: 2018-09-10

Phase 4

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

TerminatedNCT02985242

Hannover Medical SchoolDiabetes Mellitus, Type II

Start: 2017-06-12End: 2018-08-16Updated: 2018-09-27

JAMA Cardiology2024-01-0313 citations

Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials

Stroke2023-07-149 citations

Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk

Journal of Diabetes and its Complications2022-08-313 citations

Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study.

2021-10-2724 citations

Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.

2021-02-0932 citations

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

JAMA2019-09-19576 citations

Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial

Diabetes Obesity and Metabolism2018-08-0914 citations

Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.

2018-06-0134 citations

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

2018-03-1455 citations

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

Cardiovascular Diabetology2017-01-2137 citations

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA<sup>®</sup>)

Diabetes and Vascular Disease Research2015-03-15204 citations

P4‐331: RELATIONSHIP BETWEEN GLYCAEMIC CONTROL AND COGNITIVE FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AT ELEVATED CARDIOVASCULAR RISK

Alzheimer s & Dementia2014-07-011 citations

Cardiovascular Safety of Linagliptin Demonstrated in Pooled Analysis

MD Conference Express2013-11-01

Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus

Expert Review of Endocrinology & Metabolism2013-07-01

Glimepiride Placebo

Sponsors

Conditions

Phase 3

Phase 4

Related Papers